Abstract:
Disclosed herein are methods and compositions for the delivery of polypeptides, including vaccine candidate polypeptides, into mammalian cells comprising the use of photosensitized trypanosomatid organisms. Also disclosed are methods of treatment of trypanosomatid infections comprising administering phthalocyanine compounds or phthalocyanine-treated trypanosomatid microorganisms as vaccines, as well as and polypeptide delivery vectors comprising phthalocyanine-treated trypanosomatid microorganisms.
Abstract:
The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.
Abstract:
Increasing evidence indicates that Parkinson's disease (PD) and type 2 diabetes (T2DM) share dysregulated molecular networks. 84 genes shared between PD and T2DM were identified from curated disease-gene databases. Nitric oxide biosynthesis, lipid and carbohydrate metabolism, insulin secretion and inflammation were identified as common dysregulated pathways. A network prioritization approach was implemented to rank genes according to their distance to seed genes and their involvement in common biological pathways. This disclosure reinforces the idea that shared molecular networks between PD and T2DM provide an additional source of biologically meaningful biomarkers.
Abstract:
The present disclosure provides a system including one or more sensors, a mounting system configured to removeably mount a computing device such that a camera of the computing device is positioned facing an eye of a subject, and a control system. The control system is configured to (a) receive sensor data from the one or more sensors, (b) determine whether the sensor data is indicative of balance instability of the subject, (c) track a position of the eye of the subject to assess vestibular dysfunction, (d) determine whether the camera data is indicative of vestibular dysfunction of the subject, and (e) in response to (i) the sensor data being indicative of balance instability of the subject and/or (ii) the camera data being indicative of vestibular dysfunction of the subject, display an indication of symptoms that are characteristic of a traumatic brain injury or concussion.
Abstract:
A method of treating and attenuating L-DOPA-induced dyskinesia, comprising administering an effective dose of at least one pharmacological agent, e.g., vilazodone, having serotonin-specific reuptake inhibition (SSRI) and serotonin receptor 1A (5-HT1AR) partial agonism activity, in conjunction with L-DOPA. Other agents, such as an L-DOPA decarboxylase inhibitor, e.g., carbidopa, or other adjunct treatments may also be provided.
Abstract:
The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.
Abstract:
A method of performing cardiopulmonary resuscitation on a mammalian subject including the step of delivering an effective amount of a gliflozin solution during cardiac resuscitation through an intravenous or intraosseous route.
Abstract:
The present disclosure relates to a system for repetitive loading of a prosthetic socket to test the durability of the prosthetic socket. The system includes a base and a load cell coupled to the base. The system further includes a first coupling mechanism positioned vertically above the load cell, and a second coupling mechanism positioned vertically above the first coupling mechanism. The first coupling mechanism is configured to be removably coupled to a first end of the prosthetic socket, and the second coupling mechanism is configured to be removably coupled to a second end of the prosthetic socket. The system further includes a rod having a first end and a second end opposite the first end. The first end of the rod is coupled to the second coupling mechanism. The system further includes a motor coupled to the second end of the rod, a support structure extending vertically from the base, and an actuator coupled to the support structure such that the actuator is positioned vertically above the second coupling mechanism. The system further includes a curved rail coupled to the actuator and positioned between the actuator and the second coupling mechanism. The curved rail is configured to contact the second coupling mechanism along an arc defined by the curved rail such that the second coupling mechanism moves along the arc when the motor moves the rod.
Abstract:
The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.
Abstract:
The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing and/or expression of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.